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Association Between Efavirenz-Based Compared With Nevirapine-Based
Antiretroviral Regimens and Virological Failure in HIV-Infected Children
Abstract
Importance
Worldwide, the nonnucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz and nevirapine are
commonly used in first-line antiretroviral regimens in both adults and children with human
immunodeficiency virus (HIV) infection. Data on the comparative effectiveness of these medications in
children are limited.
Objective
To investigate whether virological failure is more likely among children who initiated 1 or the other NNRTI-
based HIV treatment.
Design, Setting, and Participants
Retrospective cohort study of children (aged 3–16 years) who initiated efavirenz-based (n=421) or
nevirapine-based (n=383) treatment between April 2002 and January 2011 at a large pediatric HIV care
setting in Botswana.
Main Outcomes and Measures
The primary outcome was time from initiation of therapy to virological failure. Virological failure was defined
as lack of plasma HIV RNA suppression to less than 400 copies/mL by 6 months or confirmed HIV RNA of
400 copies/mL or greater after suppression. Cox proportional hazards regression analysis compared time to
virological failure by regimen. Multivariable Cox regression controlled for age, sex, baseline immunologic
category, baseline clinical category, baseline viral load, nutritional status, NRTIs used, receipt of single-dose
nevirapine, and treatment for tuberculosis.
Results
With a median follow-up time of 69 months (range, 6–112 months; interquartile range, 23–87 months), 57
children (13.5%; 95% CI, 10.4%–17.2%) initiating treatment with efavirenz and 101 children (26.4%; 95%
CI, 22.0%–31.1%) initiating treatment with nevirapine had virological failure. There were 11 children (2.6%;
95% CI, 1.3%–4.6%) receiving efavirenz and 20 children (5.2%; 95% CI, 3.2%–7.9%) receiving nevirapine
who never achieved virological suppression. The Cox proportional hazard ratio for the combined virological
failure end point was 2.0 (95% CI, 1.4–2.7; log rank P
Conclusions and Relevance
Among children aged 3 to 16 years infected with HIV and treated at a clinic in Botswana, the use of efavirenz
compared with nevirapine as initial antiretroviral treatment was associated with less virological failure. These
findings may warrant additional research evaluating the use of efavirenz and nevirapine for pediatric patients.
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Abstract
Importance—Worldwide, the nonnucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz
and nevirapine are commonly used in first-line antiretroviral regimens in both adults and children
with human immunodeficiency virus (HIV) infection. Data on the comparative effectiveness of
these medications in children are limited.
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Objective—To investigate whether virological failure is more likely among children who
initiated 1 or the other NNRTI-based HIV treatment.
Design, Setting, and Participants—Retrospective cohort study of children (aged 3–16 years)
who initiated efavirenz-based (n=421) or nevirapine-based (n=383) treatment between April 2002
and January 2011 at a large pediatric HIV care setting in Botswana.
Main Outcomes and Measures—The primary outcome was time from initiation of therapy to
virological failure. Virological failure was defined as lack of plasma HIV RNA suppression to less
than 400 copies/mL by 6 months or confirmed HIV RNA of 400 copies/mL or greater after
suppression. Cox proportional hazards regression analysis compared time to virological failure by
regimen. Multivariable Cox regression controlled for age, sex, baseline immunologic category,
baseline clinical category, baseline viral load, nutritional status, NRTIs used, receipt of single-
dose nevirapine, and treatment for tuberculosis.
Results—With a median follow-up time of 69 months (range, 6–112 months; interquartile range,
23–87 months), 57 children (13.5%; 95% CI, 10.4%–17.2%) initiating treatment with efavirenz
and 101 children (26.4%; 95% CI, 22.0%–31.1%) initiating treatment with nevirapine had
virological failure. There were 11 children (2.6%; 95% CI, 1.3%–4.6%) receiving efavirenz and
20 children (5.2%; 95% CI, 3.2%–7.9%) receiving nevirapine who never achieved virological
suppression. The Cox proportional hazard ratio for the combined virological failure end point was
2.0 (95% CI, 1.4–2.7; log rank P<.001, favoring efavirenz). None of the measured covariates
affected the estimated hazard ratio in the multivariable analyses.
Conclusions and Relevance—Among children aged 3 to 16 years infected with HIV and
treated at a clinic in Botswana, the use of efavirenz compared with nevirapine as initial
antiretroviral treatment was associated with less virological failure. These findings may warrant
additional research evaluating the use of efavirenz and nevirapine for pediatric patients.
MORE THAN 2 MILLION children worldwide are infected with human immunodeficiency virus (HIV),
approximately 90% of whom live in sub-Saharan Africa.1,2 The scale-up of pediatric
antiretroviral treatment in Africa has been lifesaving for children.3,4 Critical review of long-
term outcomes from the first children to receive HIV treatment in this region may help to
guide treatment program improvements.
The World Health Organization (WHO) recommends that children older than 3 years
receive 1 of 2 nonnucleoside reverse transcriptase inhibitors (NNRTIs), nevirapine or
efavirenz, and 2 drugs in the NRTI class.5 Most countries favor nevirapine-based regimens
for the majority of children due to perceived comparable effectiveness at lower cost.6
Adult studies comparing efavirenz with nevirapine have shown mixed results.6–9 However,
a pooled analysis of 1688 patients in 7 randomized controlled trials showed no difference in
virological outcomes between the 2 medications.10
Limited data are available regarding the relative effectiveness of the 2 NNRTI options in
children. The only published outcomes study comparing efavirenz and nevirapine-based
therapies in children included those younger than 3 years, for whom first-line NNRTI-based
therapy is no longer the standard of care in some parts of the world.11,12 Those children in
the study receiving a generic fixed-dose combination of nevirapine, stavudine, and
lamivudine had worse 1-year outcomes than those receiving efavirenz-based treatment (odds
ratio, 2.5; 95% CI, 1.2–4.9).13
Botswana was one of the first African countries to offer treatment to children and thus has
some of the longest-term treatment outcomes data. Until 2012, the Botswana National HIV/
AIDS Treatment Guidelines recommended either nevirapine or efavirenz.14 Pediatric fixed-
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dose combinations have not been used. The NNRTI choice was determined by the clinician
initiating treatment. We aimed to determine whether there was a difference in time to
virological failure between children initiating nevirapine vs efavirenz-based treatment in
Botswana.
METHODS
Study Design and Setting
We conducted a retrospective cohort study of children who received treatment at the
Botswana-Baylor Children's Clinical Centre of Excellence in Gaborone, Botswana, between
April 2002 and January 2011.15 Virtually all the children are thought to have been
perinatally infected. Eligibility criteria included confirmed HIV infection, age of 3 to 16
years at initiation of HIV treatment, and initiation of first-line NNRTI-based therapy. Some
patients (n=45) were included in a prior study of genotypic resistance testing after
virological failure.16 Children younger than 3 years were excluded because efavirenz is not
recommended for that age group. The reasons for exclusion of clinic patients from the study
cohort are indicated in Figure 1.
A large number of patients with baseline characteristics similar to those of patients included
in our cohort were enrolled in a clinical trial with first-line protease inhibitor–based
treatment. As per the national treatment guidelines,14,17 most patients concurrently received
the NRTIs zidovudine and lamivudine. Stavudine was substituted for zidovudine when
baseline anemia was moderate or severe. Other NRTI substitutions were allowed, but were
rarely used (Table 1).
Drug doses were calculated based on national guidelines. Prior to 2008, nevirapine doses
were based on the child's weight (7 mg/kg for age <8 years and 4 mg/kg for age ≥8 years) or
body surface area (120–200 mg/m2) and efavirenz dosing charts were used.17 After 2008,
WHO guidelines were used.5 Efavirenz became the guideline-preferred first-line NNRTI for
adults after 2008, but efavirenz and nevirapine were still recommended equally as first-line
therapy for children.14 Prior to 2008, adherence was not recorded; after 2008, pill counts
were recorded at most clinical visits.
The study was reviewed and approved by the Botswana Health Research Development
Committee and the institutional review boards of the University of Pennsylvania and Baylor
College of Medicine. Informed consent was waived because the study provided no more
than minimal risk to patients, the waiver did not adversely affect the rights and welfare of
patients, and the research could not practicably be performed without having the waiver.
Data were obtained from electronic and paper medical records. A review of at least 10% of
all nonprimary source data (ie, data in an electronic database that had been transcribed from
paper records) demonstrated greater than 95% accuracy.
Variables of Interest
For the primary analysis, treatment was classified based on the starting regimen. The
primary outcome was time from initiation of therapy to virological failure. Virological
failure was defined by lack of plasma HIV RNA suppression to less than 400 copies/mL by
6 months or confirmed viral load of 400 copies/mL or greater after initial suppression. Most
patients had viral load measurements at both 3 and 6 months of treatment.
Patients who did not achieve virological suppression at the 6-month measurement and who
lacked a 3-month value had another viral load measurement to confirm lack of suppression.
Patients withasingleviralloadofgreaterthan400 copies/mL preceding death or loss to follow-
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up were considered to have had virological failure. Patients who died or were lost to follow-
up whose viral load was undetectable before death or loss to follow-up were not considered
to have experienced virological failure. Patients were censored at the time of death, loss to
follow-up, or at the end of observation, whichever came first.
Age was analyzed as a continuous variable. Baseline Centers for Disease Control and
Prevention (CDC) immunologic category was defined by age-specific classifications based
on CD4 cell absolute counts and percentage.12 Discordance between the classification based
on absolute count or percentage was classified as the lower of the 2. The CDC clinical
category was established based on the child's history of HIV-associated clinical symptoms.
Category C indicates severe symptoms, category B indicates moderate symptoms, category
A indicates mild symptoms, and category N indicates no symptoms or a single category A
symptom.18 Viral loads had an upper limit of 750 000 copies/mL; baseline viral load was
log-transformed and analyzed both as a continuous variable and as having 750 000 copies/
mL or greater or not.
Of note, the Botswana national guidelines mandated that baseline viral loads no longer be
obtained after 2008. Exposure to single-dose nevirapine for prevention of mother-to-child
transmission was based on receipt of nevirapine by the mother during labor or the infant
after birth. The NRTI regimen was dichotomized as zidovudine and lamivudine or other.
Tuberculosis treatment was defined as receipt of a rifampicin-containing regimen at any
time following initiation of antiretroviral therapy.
Baseline acute and chronic nutritional status was calculated by determining z scores for
body mass index (BMI; calculated as weight in kilograms divided by height in meters
squared) for age and height for age, respectively, using WHO AnthroPlus software version
3.2.2. For children younger than 5 years, weight-for-height z scores were substituted for
BMI because BMI does not increase monotonically in young children. The reasons for
switching regimens were abstracted from medical chart notes. Pill count adherence was
averaged for each patient with adherence data.
Statistical Analysis
Characteristics of children initiating therapy with efavirenz- or nevirapine-based treatments
were compared using t tests and rank sum tests for continuous data and χ2 tests for
dichotomous or polytomous data. The primary end point was time to virological failure. Cox
proportional hazards models were used to compare time to event and to control for
covariates. All demographic and baseline clinical variables in Table 1 were evaluated as
covariates. Time to virological failure was compared between groups univariately using
Kaplan-Meier survival plots with the log-rank test. Covariates were considered for inclusion
in the final hazard model on the basis of an unadjusted association with virological failure
(P<.25).
Effect modification was tested by including main effects and interaction terms in the Cox
models. Confounding was assessed by evaluating the association of each covariate with the
exposure (drug) and the outcome (virological failure), as well as by assessing whether
inclusion in the models affected the hazard ratio (HR). We also conducted analyses on the
primary outcome using propensity scores to control for potential confounding, using a Cox
model with 3 different propensity score models. The models were selected based on all
potential confounders, and then the most plausible potential confounders.19,20 The
proportional hazards assumption was assessed for all Cox models using Schoenfeld
residuals.21 Missing data imputation was attempted for covariates as required, but the
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models used did not converge.22 Extensive sensitivity analyses were performed to assess the
effect of missing data on the results observed with available data.
We used χ2 tests to compare the regimens with regard to the proportion with virological
failure at any time point. Secondary analyses, otherwise identical to those described above,
were performed to assess the effect of drug switches.  These analyses assigned all patients
who had a regimen switch to the NNRTI group to which they switched. Further secondary
analyses characterized patients who died or were lost to follow-up with their last viral load
undetectable as having virological failure. All analyses were 2-sided with a P value of less
than .05 considered statistically significant. Analyses were performed with Stata version 11
software (StataCorp).
With a mean time to virological failure of 24 months in the reference group and a fixed
sample size of 800 (380 on one regimen and 420 on the other), we had greater than 80%
power to detect a HR for time to virological failure of less than 0.8 or greater than 1.2
among patients for each of the drug regimens and a 2-sided α level of .05.
RESULTS
There were 804 black African (Tswana) children who initiated treatment between April
2002 and January 2011 who were included in the primary analysis, with a median follow-up
time of 69 months (range, 6–112 months; interquartile range, 23–87 months). The
characteristics of the cohort are outlined in Table 1. After 2008, fewer patients received
nevirapine and more patients taking nevirapine experienced treatment failure and thus were
censored by 2008. More patients initiated treatment with efavirenz than nevirapine after
2008, resulting in more missing baseline viral loads in the efavirenz group.
There were 158 children (19.7%; 95% CI, 17.0%–22.6%) who experienced virological
failure; 57 children (13.5%; 95% CI, 10.4%–17.2%) in the efavirenz group and 101 children
(26.4%; 95% CI, 22.0%–31.1%) in the nevirapine group (P<.001). The time to virological
failure was shorter among patients taking nevirapine vs those taking efavirenz (Figure 2).
The Cox proportional HR for the combined virological failure end point was 2.0 (95% CI,
1.4–2.7; log-rank P<.001). There were 11 children (2.6%; 95% CI, 1.3%–4.6%) receiving
efavirenz and 20 children (5.2%; 95% CI, 3.2%–7.9%) receiving nevirapine who never
achieved virological suppression.
The virological failure rates at 1, 2, and 5 years with efavirenz were 6.7% (95% CI, 4.5%–
9.5%), 10.2% (95% CI, 7.5%–13.5%), and 12.8% (95% CI, 9.8%–16.4%), respectively; and
with nevirapine were 12.8% (95% CI, 9.6%–16.6%), 19.8% (95% CI, 16.0%–24.2%), and
25.1% (95% CI, 20.8%–29.7%), respectively. The absolute risk differences at the 3 time
points were 6.1%, 9.6%, and 12.3%, all favoring efavirenz.
Adjusting for age, sex, baseline immunologic category, baseline clinical category, baseline
viral load, nutritional status, NRTIs used, receipt of single-dose nevirapine, and tuberculosis
treatment did not significantly change the HR. Similarly, the use of propensity scores did not
appreciably change the results (eTable at http://www.jama.com).
When stratified by sex, time to virological failure was statistically significantly shorter for
the nevirapine group vs the efavirenz group in both males (HR, 2.5 [95% CI, 1.6–4.0]; P<.
001) and females (HR, 1.8 [95% CI, 1.1–2.8]; P=.02) (Figure 3). Although the shorter time
to virological failure with nevirapine was more pronounced in males than in females, the
medication group×sex interaction term in the Cox model was not statistically significant
(P=.25).
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The virological failure rates at 1, 2, and 5 years among males receiving efavirenz were 6.9%
(95% CI, 4.1%–10.8%), 10.2% (95% CI, 6.7%–14.6%), and 11.8% (95% CI, 8.0%–16.5%),
respectively; and among males receiving nevirapine were 18.0% (95% CI, 12.3%–24.9%),
24.4% (95% CI, 17.9%–31.9%), and 30.1% (95% CI, 23.1%–38.0%), respectively. The
absolute risk difference at the 3 time points in males was 11.1%, 14.2%, and 18.3%,
respectively.
The failure rates at 1, 2, and 5 years among females receiving efavirenz were 6.3% (95% CI,
3.2%–11.0%), 10.3% (95% CI, 6.2%–15.8%), and 14.3% (95% CI, 9.5%–20.4%),
respectively; and among females receiving nevirapine were 9.3% (95% CI, 5.8%–13.8%),
16.7% (95% CI, 12.1%–22.2%), and 21.6% (95% CI, 16.4%–27.5%), respectively. The
absolute risk difference at the 3 time points in females was 3.0%, 6.4%, and 7.3%,
respectively. Of the 214 children (26.6%) who initiated treatment after their 10th birthday,
105 (49.1%) were female.
For those aged 10 years or older at initiation of antiretroviral treatment, more girls than boys
initiated nevirapine (68 [65%] vs 22 [20%], respectively; P<.001). However, a similar
percentage experienced treatment failure who were younger than 10 years (112 patients;
19.0% [95% CI, 15.9%–22.4%]) and aged 10 years or older (46 patients; 21.5% [95% CI,
16.2%–27.6%]) (P=.43). Older children did not experience treatment failure statistically
significantly more rapidly than younger children (HR, 1.4 [95% CI, 1.0–1.9]; P=.09).
In a subanalysis of children younger than 10 years, 12.6% experienced efavirenz-based
treatment failure vs 25% of children receiving nevirapine-based treatment (P<.001). For the
children who were aged 10 years or older, 15.1% experienced efavirenz-based treatment
failure vs 29% receiving nevirapine-based treatment (P=.01). The HR for treatment failure
in children younger than 10 years was 2.0 (95% CI, 1.4–2.9;P<.001). The HR for treatment
failure in the children aged 10 years or older was 2.3 (95% CI, 1.3–4.0; P=.003).
Sex-specific differences regarding choice of NNRTI for the 590 children who initiated
treatment when younger than 10 years were much less pronounced, with nevirapine used in
159 girls (54%) and 134 boys (46%) (P=.06). A higher proportion of patients began
efavirenz after 2008 (Table 1); however, the significant difference in virological failure rates
between groups persisted after excluding those who initiated treatment with efavirenz after
2008 (16.7% [95% CI, 12.7%–21.4%] receiving efavirenz vs 29.2% [95% CI, 24.4%–
34.4%] receiving nevirapine; P<.001).
Eight patients who died during the first 6 months and 2 patients who died during the follow-
up interval were not included in the primary analysis. There were 13 patients who were lost
to follow-up; 4 patients prior to receiving 6 months of treatment. Counting death and loss to
follow-up with undetectable viral loads as having virological failure had little effect on the
failure risk rate (HR, 2.1 [95% CI, 1.5–2.9] vs HR, 2.0 [95% CI, 1.4–2.7] in the primary
analysis). The absolute risk when death and loss to follow-up were counted as failure was
13.5% (95% CI, 10.4%–17.2%) of those in the efavirenz group and 27.9% (95% CI, 23.5%–
32.7%) of those in the nevirapine group. Age at time of virological failure was similar for
males and females (mean age, 9.5 vs 10.3 years; P=.14). The virological failure rate among
patients receiving tuberculosis treatment (23/96; 24.0% [95% CI, 15.8%–33.7%]) was also
similar to the rate in those not receiving it (135/704; 19.1% [95% CI, 16.3%–22.3%]) (P=.
27). All Cox models satisfied the proportional hazards assumption.
Regimen Switches
There were 39 patients (5%) who switched NNRTIs during the follow-up period and 3
patients (7.7%; 95% CI, 1.6%–20.9%) who experienced virological failure after switching
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regimens. Of those with virological failure, 2 patients switched from efavirenz to nevirapine
and 1 patient switched from nevirapine to efavirenz. There was no significant change in the
hazard of virological failure by regimen when exposure was classified based on the final
NNRTI received rather than the initial NNRTI (HR, 1.9; 95% CI, 1.4–2.7). The reasons for
the NNRTI switches are outlined in Table 2. The most common reasons for changing
regimens were concern about the teratogenic effects of efavirenz in postpubertal girls and
efavirenz-related gynecomastia.
DISCUSSION
In this large cohort of children infected with HIV, time to virological failure was longer
among children receiving efavirenz vs nevirapine. With the majority of the world's children
receiving nevirapine-based antiretroviral therapy, these findings may have significant public
health importance.23
Recent publications have suggested that wider use of efavirenz among adults in low-
resource settings with high prevalence of HIV infection may improve outcomes and be cost-
effective.24,25 Tuberculosis treatment has played an important role with better virological
outcomes among adults with tuberculosis who are receiving efavirenz-based vs nevirapine-
based antiretroviral therapy.26 This finding is of great importance for patients with HIV in
sub-Saharan Africa where there is a high prevalence of co-infection.27 However, in our
study, higher virological failure rates were not explained by children receiving tuberculosis
therapy and nevirapine concurrently. Baseline resistance also seems an unlikely contributor
because only 2.2% of our cohort were known to have received single-dose nevirapine.
Therefore, other explanations must exist.
Adherence data for our cohort were limited, especially for those with virological failure.
Available pill count adherence rates were very high and showed little variability. Therefore,
we are unable to comment directly on the role of adherence in the observed outcomes.
We considered the potential for differences in NNRTI choice based on patient
characteristics to be the greatest limitation of our study. The most likely source of important
differential prescribing was expected to be disproportionate use of nevirapine for girls
nearing the age of childbearing potential due to concerns for the teratogenic effects of
efavirenz. We further expected that having a higher proportion of older girls taking
nevirapine might bias in favor of efavirenz because adolescents may have worse adherence
than younger children. However, regimen-specific differences were actually somewhat more
pronounced among males than females, with males taking nevirapine having the worst
outcomes.
Even though this study was limited to a single site, we believe that the findings will be
generalizable to other settings with high HIV prevalence in most respects. Patients studied
are similar to those in other high-prevalence African countries. Although Botswana is a
moderate-income, rather than a low-income nation, children receiving care in the national
antiretroviral treatment program are those whose families do not have private insurance and
primarily represent lower socioeconomic strata. In our study, 43% of patients had height-
forage z scores of less than − SDs on the WHO growth curves, indicating chronic
malnutrition.28 Subtype of HIV may have an effect on treatment outcomes. In Botswana,
most people with HIV have subtype Cinfection, which is one of the most common subtypes
worldwide and the most common in Southern Africa.29 The HIV subtype C and D infections
have been noted to be more virulent than other common viral subtypes.30,31 Although data
on subtype-specific treatment outcomes are scarce, there is evidence that patients with
subtype D virus have worse outcomes than patients with less virulent subtypes.30,31 More
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potent drugs may be necessary to ensure optimal treatment outcomes in patients with more
aggressive virus.
The greatest limitation regarding generalizability of our cohort probably relates to the
clinical site's active follow-up program for patients who miss clinic appointments. Due in
large part to these efforts, the loss to follow-up rate in this cohort was less than 2% over the
almost 10-year period of observation. Unmeasured potential confounding variables must be
considered as limitations of all retrospective cohort studies. At our study site, there are
multiple clinicians; patients do not routinely see the same clinicians at follow-up visits.
Thus, clinician-specific differences should have minimal effects on treatment outcomes.
In other settings in which both efavirenz and nevirapine are being used for pediatric
treatment, additional studies should be conducted to confirm or refute these results. Further
studies assessing reasons for increased virological failure rates should also be undertaken to
help provide insight into mechanisms of treatment failure in this setting. The finding of
increased rates of virological failure among children receiving nevirapine suggests that more
work should be done to make efavirenz a cost-effective option for pediatric antiretroviral
treatment programs in resource-limited settings.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Reasons for Exclusion of Clinic Patients From the Study Cohort
aThe patients who initiated a protease inhibitor–based treatment were enrolled in a clinical
trial. A few patients began taking 2 nucleoside reverse transcriptase inhibitors before highly
active antiretroviral therapy was available.
bIncluded in death and loss to follow-up counted as virological failure subanalysis.
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Figure 2.
Kaplan-Meier Survival Estimate for Proportion Without Virological Failure in Total Cohort
Virological failure was defined by lack of plasma HIV RNA suppression to less than 400
copies/mL by 6 months or confirmed plasma HIV RNA of 400 copies/mL or greater after
suppression. Time to virological failure was the time of the 6-month viral load for those who
did not achieve virological suppression by 6 months. For those with subsequent virological
rebound, time to virological failure was defined as the time of the first elevated viral load
after initial virological suppression.
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Figure 3.
Kaplan-Meier Survival Estimates for Proportion Without Virological Failure by Sex
Virological failure was defined by lack of plasma HIV RNA suppression to less than 400
copies/mL by 6 months or confirmed plasma HIV RNA of 400 copies/mL or greater after
suppression. Time to virological failure was the time of the 6-month viral load for those who
did not achieve virological suppression by 6 months. For those with subsequent virological
rebound, time to virological failure was defined as the time of the first elevated viral load
after initial virological suppression.
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Table 1
Characteristics of Children Initiating Antiretroviral Therapy
No. (%) of Patientsa
Efavirenz (n = 421) Nevirapine (n = 383) P Valuesb
Age, median (IQR), y 8.1 (6.0–10.5) 7.0 (4.8–9.8) <.001
Antiretroviral therapy initiated before 2008 299 (71.0) 339 (88.5) <.001
Female sex 175 (43.5) 227 (56.5) <.001
Baseline CD4%, median (IQR) (n = 409) 13 (8 to 20) (n = 368) 15 (9 to 22) .003
c
Baseline CDC immunologic category
d
 1 34 (8.1) 51 (13.3)
.03
c
 2 123 (29.2) 126 (32.9)
 3 262 (62.2) 203 (53.0)
 Missing 2 (0.5) 3 (0.8)
Baseline CDC clinical category
e
 N 29 (6.9) 10 (2.6)
<.001
c
 A 40 (9.5) 44 (11.5)
 B 84 (20.0) 102 (26.6)
 C 164 (39.0) 173 (45.2)
 Missing 104 (24.7) 54 (14.1)
Baseline HIV RNA, copies/mL (n = 115) (n = 175)
 Log10, median (IQR) 5.2 (4.8 to 5.6) 5.3 (4.9 to 5.7) .32
 >750 000 15 (13.0) 16 (9.1) .35
z Score, mean (SD)
 Height for age (n = 358) −2.2 (1.3) (n = 341) −2.6 (1.7) <.001
 Weight for height or body mass index
f (n = 359) −1.0 (1.5) (n = 340) −0.8 (1.4) .16
Nucleoside reverse transcriptase inhibitors
 Zidovudine plus lamivudine 380 (90.3) 357 (93.2)
.18
 Stavudine plus lamivudine 34 (8.1) 24 (6.3)
 Tenofovir plus emtricitabine 6 (1.4) 1 (0.3)
 Abacavir plus lamivudine 1 (0.2) 0
                                JAMA. Author manuscriptt.
Lowenthal et al. Page 15
No. (%) of Patientsa
Efavirenz (n = 421) Nevirapine (n = 383) P Valuesb
 Didanosine and stavudine 0 1 (0.3)
Single-dose nevirapine
 Mother and/or baby received 7 (1.7) 11 (2.9)
.25
 None or unknown 414 (98.3) 372 (97.1)
Treated for tuberculosis during antiretroviral therapy
 Yes 65 (15.4) 31 (8.1)
.001
c No 356 (84.6) 348 (90.9)
 Missing 0 4 (1.0)
Pill count adherence, median (IQR), % doses taken
g (n = 287) 98 (97 to 99) (n = 202) 98 (98 to 99) .46
Never achieved virological suppression 11 (2.6) 20 (5.2) .06
Died 1 (0.2) 1 (0.3) .94
Lost to follow-up 0 9 (2.4) .002
Abbreviations: CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; IQR, interquartile range.
a
Unless otherwise indicated.
b
The t test was used for normally distributed continuous data, the Wilcoxon rank sum test for nonparametric continuous data, and the χ2 test for
dichotomous data.
c
Based on comparisons of available data only. Inclusion of missing data as an additional category led to minimal changes for all variables.
d
Defined by age-specific classifications based on CD4 cell absolute counts and percentage12; discordance was classified as the lower of the 2.
When the CD4 cell percentage was missing, the CDC immunologic category was determined based on the CD4 cell absolute count alone. Category
1 indicates mild or no apparent immunologic suppression; category 2, moderate immunologic suppression; and category 3, severe immunologic
suppression. For those children enrolled in the study, the following cutoffs applied for CD4 cell count and CD4 cell percentage, respectively, for
those aged 3 to 5 years: category 1,1000 cells/μL or greater (≥25%), category 2, 500 to 999 cells/μL (15%–24%), category 3, less than 500 cells/
μL (<15%); and for those aged 6 years or older: category 1, 500 cells/μL or greater (≥25%), category 2, 200 to 499 cells/μL (15%–24%), category
3, less than 200 cells/μL (<15%).
e
Category N indicates that the patient has not been symptomatic or had a single category A symptom; category A, mild symptoms; category B,
moderate symptoms; and category C, severe symptoms.18
f
Body mass index was calculated as weight in kilograms divided by height in meters squared.
g
Repeated measures for the same patient were averaged.
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Table 2
Reasons for Switching Nonnucleoside Reverse Transcriptase Inhibitors
No. (%) of Total Cohorta
Switched from efavirenz to nevirapine (n = 26)
 Puberty 13 (3.1)
 Gynecomastia 7 (1.7)
 Neuropsychiatric effects 4 (1.0)
 Out of stock 2 (0.5)
Switched from nevirapine to efavirenz (n = 13)
 Dermatologic reaction 5 (1.3)
b
 Regimen simplification 4 (1.0)
 Hepatotoxic effects 3 (0.8)
b
 Emesis 1 (0.3)
 Not documented 1 (0.3)
a
There were 421 patients who started taking efavirenz and 383 who started taking nevirapine.
b
One patient had 2 reasons for the treatment switch.
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